Med. praxi. 2020;17(3):151-156 | DOI: 10.36290/med.2020.029

Lipid-lowering therapy in selected specific groups of patients

doc. MUDr. Pavel Kraml, Ph.D.
2 . interní klinika 3. LF UK a FN Královské Vinohrady, Praha

The article deals with secondary hyperlipoproteinaemias (dyslipidaemias) in patients with chronic kidney disease (CKD), liver disease, and autoimmune rheumatic disease. In the section devoted to CKD, the pathophysiology of existing dyslipidaemia is discussed first, followed by current treatment recommendations, also taking into account end-stage renal disease patients on haemodialysis therapy and after kidney transplantation. In case of chronic liver disease, the text describes pathophysiology of dyslipidaemia and its treatment in individuals with non-alcoholic fatty liver disease (NAFLD), alcoholic disease, cirrhosis, and after liver transplantation. Regarding autoimmune rheumatic diseases, dyslipidaemia in rheumatoid arthritis, systemic lupus erythematosus, antiphospholipid syndrome, and systemic sclerosis are mentioned. The effect of immunosuppressive therapy on lipid parameters is also discussed.

Keywords: secondary hyperlipoproteinaemia, chronic kidney disease, chronic liver disease, autoimmune disease, lipid-lowering therapy, cardiovascular risk.

Published: June 18, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kraml P. Lipid-lowering therapy in selected specific groups of patients. Med. praxi. 2020;17(3):151-156. doi: 10.36290/med.2020.029.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Di Angelantonio E, Gao P, Pennells L, et al. Lipid-related markers and cardiovascular disease prediction. Emerging Risk Factors Collaboration. JAMA 2012; 307: 2499-2506.
    2. Wilkins JT, Ning H, Stone NJ, et al. Coronary heart disease risks associated with high levels of HDL cholesterol. J Am Heart Assoc 2014; 3: e000519. 10.1161/JAHA.113.00051. Go to original source... Go to PubMed...
    3. 2019 ESC/EAS Guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk. European Heart Journal 2019; 00: 1-78.
    4. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidémií z roku 2019. AtheroRev 2019; 4(3): 126-137.
    5. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351: 1296-1305. Go to original source...
    6. Colantonio LD, Baber U, Banach M, et al. Contrasting cholesterol management guidelines for adults with CKD. J Am Soc Nephrol 2015; 26: 1173-1180. Go to original source... Go to PubMed...
    7. Locatelli F, Canaud B, Eckardt KU, et al. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 2003; 18: 1272-1280. Go to original source...
    8. Cases A, Coll E. Dyslipidemia and the progression of renal disease in chronic renal failure patients. Kidney Int Suppl. 2005; (99): S87-S93. Go to original source...
    9. Kwan BC, Kronenberg F, Beddhu S, Cheung AK. Lipoprotein metabolism and lipid management in chronic kidney disease. J Am Soc Nephrol 2007; 18: 1246-1261. Go to original source... Go to PubMed...
    10. Nitta K. Clinical assessment and management of dyslipidemia in patients with chronic kidney disease. Clin Exp Nephrol 2012; 16: 522-529. Go to original source...
    11. Kronenberg F, Kuen E, Ritz E, et al. Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J. Am. Soc. Nephrol. 2000; 11(1): 105-115. Go to original source... Go to PubMed...
    12. Kronenberg F. HDL in CKD-The Devil is in the Detail. JASN 2018; 29(5): 1356-1371. Go to original source... Go to PubMed...
    13. Tsimihodimos V, Mitrogianni Z, Elisaf M. Dyslipidemia associated with chronic kidney disease. Open Cardiovasc Med J. 2011; 5: 41-48. Go to original source... Go to PubMed...
    14. Thompson M, Ray U, Yu R, et al. Kidney Function as a Determinant of HDL and Triglyceride Concentrations in the Australian Population. J Clin Med 2016; 5(3): E35. doi: 10.3390/jcm5030035 Go to original source... Go to PubMed...
    15. Mikolašević I, Lukenda V, Sladoje-Martinović B, et al. Metabolic complications after solid organ transplantation. Medicina Fluminensis. 2014; 50: 61-66.
    16. Kahwaji JM, Dudek RR. How can we manage hyperlipidemia and avoid rhabdomyolysis in transplant patients? Perm J. 2006; 10: 26-28. Go to original source...
    17. Mesquita J, Varela A, Medina JL. Dyslipidemia in renal disease: causes, consequences and treatment. Endocrinol Nutr. 2010; 57: 440-448. Go to original source...
    18. Tonelli M, Wanner C. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. Ann Intern Med 2014; 160: 182. Go to original source...
    19. Messow CM, Isles C. Meta-analysis of statins in chronic kidney disease: who benefits? International Journal of Medicine 2017; 110(8): 493-500. Go to original source...
    20. Pfizer: Lipitor prescribing information. Updated March 2015.
    21. AstraZeneca: Crestor prescribing information. Updated April 2016.
    22. Baigent C, Landray MJ, Reith C, et al. SHARP Investigatiors. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial. Lancet 2011; 377: 2181-2192. Go to original source...
    23. Abujrad H, Mayne J, Ruzicka M, et al. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. Atherosclerosis 2014; 233: 123-129. Go to original source...
    24. Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol 2019; 73(23): 2961-2970. Go to original source...
    25. Ray KK, Ginsberg HN, Davidson MH, et al. Reductions in atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control. Circulation 2016; 134: 1931-1943. Go to original source...
    26. Jun M, Zhu B, Tonelli M, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. JACC 2012; 60(20): 2061-2071. Go to original source... Go to PubMed...
    27. Davis TM, Ting R, Best JD, et al. Fenofibrate Intervention and Event Lowering in Diabetes Study Investigators: Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia 2011; 54: 280-290. Go to original source...
    28. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group K/DOQI clinical practice guidelines for managing dyslipidemia in chronic kidney disease. Am J Kidney Dis. 2003; 41: 1-237.
    29. Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013; 3: 259-305.
    30. Soohoo M, Maradi H, Obi Y, et al. Statin Therapy Before Transition to End-Stage Renal Disease With Posttransitional Outcomes. JAHA 2019; 8: e011869. Go to original source... Go to PubMed...
    31. Holdaas H, Fellström B, Jardine AG. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003; 361(9374): 2024-2031. Go to original source...
    32. Demir M, Lang S, Steffen HM. Nonalcoholic fatty liver disease - current status and future directions. J Dig Dis 2015; 16 (10): 541-557. Go to original source...
    33. Masarone M, Federico A, Abenavoli L, et al. Non-alcoholic fatty liver: epidemiology and natural history. Rev Recent Clin Trials 2014; 9(3): 126-133. Go to original source...
    34. Zhang QQ, Lu LG. Nonalcoholic fatty liver disease: dyslipidemia, risk for cardiovascular complications, and treatment stratégy. J Clin Transl Hepatol 2015; 3(1): 78-84. Go to original source...
    35. Nikolic D, Katsiki N, Montalto G, Isenovic ER, Mikhailidis DP, Rizzo M. Lipoprotein subfractions in metabolic syndrome and obesity: clinical significance and therapeutic approaches. Nutrients 2013; 5(3): 928-948. Go to original source... Go to PubMed...
    36. Ress C, Kaser S. Mechanisms of intrahepatic triglyceride accumulation. World J Gastroenterol 2016; 22 (4): 1664-1673. Go to original source...
    37. Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2015; 65(2015): 1062-1079. Go to original source...
    38. Stojsavljević S, Gomerčić Palčić M, Virović L, et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(48) (2014): 18070-18091. Go to original source...
    39. Lau E, Carvalho D, Freitas P. Gut microbiota: Association with NAFLD and metabolic disturbances Biomed Res Int., 2015: 979515. doi 10.1155/2015/979515 Go to original source... Go to PubMed...
    40. Jaruvongavanich V, Wirunsawanya K, Sanguankeo A, et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification: A systemic review and meta-analysis. Dig Liver Dis. 2016; 48: 1410-1417. Go to original source...
    41. Sookoian S, Pirola CJ. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: A systematic review. J Hepatol 2008; 49(4): 600-607. Go to original source... Go to PubMed...
    42. Cai J, Zhang S, Huang W. Association between nonalcoholic fatty liver disease and carotid atherosclerosis: A meta-analysis. Int J Clin Exp Med 2015; 8(5): 7673-7678.
    43. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological ssociation. Hepatology 2012; 55(6): 2005-2023. Go to original source... Go to PubMed...
    44. Katsiki N, Mikhalidis DP, Mantzoros CS. Non-alcoholic fatty liver disease and dyslipidemia: An update. Metabolism 2016; 65(8): 1109-1123. Go to original source...
    45. Park H, Shima T, Yamaguchi K, et al. Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease. J Gastroenterol 2011; 46(1): 101-107. Go to original source... Go to PubMed...
    46. Kamran H, Kupferstein E, Starma P, et al. Statins and New-Onset Diabetes in Cardiovascular and Kidney Disease Cohorts. A Meta-Analysis. Cardiorenal Med 2018; 8: 105-112. Go to original source... Go to PubMed...
    47. Athyros VG, Tziomalos K, Gossios TD, et al. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin And Coronary Heart Disease Evaluation (GREACE) Study: A post-hoc analysis. Lancet 2010; 376: 1916-1922. Go to original source...
    48. Tikkanen MJ, Fayyad R, Faergeman O, et al. Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels. Int J Cardiol 2013; 168: 3846-3852. Go to original source...
    49. Dongiovanni P, Petta S,Mannisto V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol 2015; 63(3): 705-712. Go to original source... Go to PubMed...
    50. Kargiotis K, Athyros VG, Giouleme O, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome World J Gastroenterol 2015; 21(25): 7860-7868. Go to original source...
    51. Gandhi N, Lenton R, Bhartia M, et al. Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome. Springerplus 2014; 3: 14. Go to original source... Go to PubMed...
    52. Fuchs M. Non-Alcoholic Fatty Liver Disease: The Bile Acid-Activated Farnesoid X Receptor as an Emerging Treatment Target. J Lipids. 2012; 2012: 934396. Go to original source...
    53. Osna NA, Donohue TM, Kharbanda KK. Alcoholic Liver Disease; Pathogenesis and Current Management. Alcohol Res 2017; 38(2): 147-161.
    54. Bessembinders K, Wielders J, van de Wiel A. Severe Hypertriglyceridemia Influenced by Alcohol (SHIBA). Alcohol and Alcoholism 2011; 46(2): 113-116.Další literatura u autora a na www.medicinapropraxi.cz Go to original source... Go to PubMed...
    55. Van de Wiel A. The effect of Alcohol on Postprandial and Fasting Triglycerides. Int J Vasc Med 2012; 2012: 862504. Go to original source...
    56. Steiner JL, Land CH. Alcohol, Adipose Tissue and Lipid Dysregulation. Biomolecules 2017; 7(1): 16. Go to original source...
    57. Joglekar K, Brannick B, Kadaria D, et al. Therapeutic plasmapheresis for hypertriglyceridemia-associated acute pancreatitis: case series and review of the literature. Ther Adv Endocrinol Metab 2017; 8(4): 59-65. Go to original source...
    58. Varghese JS, Krisnaprasad K, Upadhuyay R, Revathy MS, Jayanthi V. Lipoprotein profile in cirrhosis of Liver. Euro J Gastroenterol Hepatol 2007; 9: 521-522. Go to original source...
    59. Kasia Ch, Scaglione S. Patients with Chronic Liver Disease/Cirrhosis Should Not Take Statin Medication.Clin Liver Dis 2019; 13(4): 106-110. Go to original source...
    60. Stojakovic T, Claudel T, Putz-Bankuti C. Low-dose atorvastatin and vascular function in patients with primary biliary cirrhosis after one year treatment. Atherosclerosis 2010; 209(1): 178-183. Go to original source...
    61. Hüsing A, Kabar I, Schmidt HH. Lipids in liver transplant recipients. World J Gastroenterol 2016; 22(12): 3315-3324. Go to original source...
    62. Morrisett JD, Abdel-Fattah G, Kahan BD. Sirolimus changes lipid concentrations and lipoprotein metabolism in kidney transplant recipients. Transplant Proc 2003; 35: 143S-150S. Go to original source... Go to PubMed...
    63. Agarwal A, Ramesh Prasad GV. Post-transplant dyslipidemia: Mechanisms, diagnosis, and management. World J Transplant 2016; 6(1): 125-134. Go to original source...
    64. Glynn M, Jantz A, Summers B, Salgia R, Sulejmani N. Safety of Statin Therapy After Liver Transplantation. [abstract]. Am J Transplant. 2017; 17(suppl. 3).
    65. Warden BA, Duell PB. Management of Statin Treatment in Adult Solid Organ Transplant Recipients. National Lipid Association 2018.
    66. Singh S, Wyatt KD. Long-term Medical Management of the Liver Transplant Redipient: What the Primary Care Physician Needs to Know. Mayo Clin Proc 2012; 87(8): 779-790. Go to original source...
    67. Kavanaugh A. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann Rheum Dis 1994; 53: 551-552. Go to original source...
    68. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis-the Third National Health and Nutrition Examination Survey. J Rheumatol 2005; 32: 2311-2316. Go to PubMed...
    69. Dursunoglu D, Evrengul H, Polat B, et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005; 25: 241-245. Go to original source... Go to PubMed...
    70. Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C. Cardiovascular risk in systemic lupus erythematosus-evidence of increased oxidative stress and dyslipidaemia. Rheumatology. 2003; 42: 758-762. Go to original source...
    71. Hua X, Su J, Svenungsson E, et al. Dyslipidemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease. Scand J Rheumatol 2009; 38(3): 184-189. Go to original source...
    72. Svenungsson E, Jensen-Urstad K, Helmbürger M, et al. Risk Factors for Cardiovascular Disease in Systemic Lupus Erythematosus. Circulation 2001; 104: 1887-1893. Go to original source...
    73. Navarro-Millán I, Charles-Schoeman C, Yang S, et al. Arthritis Rheum 2013; 65(6): 1430-1438. Go to original source...
    74. Mangoni AA, Zinellu A, Sotgia S, et al. Methotrexate and Cardiovascular Protection: Current Evidence and Future Directions. Clinical Medicine Insights 2017; 9: 1-12. Go to original source...
    75. Munro R, Morrison E, McDonald AG, et al. Effect of disease modifying agents on the lipid profile of patients with rhuematoid arthritis. Ann Rheum Dis. 1997; 56: 374-377. Go to original source...
    76. Tam LS, Gladman DD, Hallatt DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol. 2000; 27: 2142-2145. Go to PubMed...
    77. Barnabe C, Martin BJ, Ghali WA. Systemic review and metaanalysis: anti-tumor necrosos factor alpha therapy and cardiovascular events in rheumatoid arthritis. Arhritis Care Res 2011; 63: 522-529. Go to original source...
    78. Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011; 13: R141. Go to original source...
    79. Jorge AM, Lu N, Keller SF. The Effect of Statin Use on Mortality in Systemic Autoimmune Rhemuatic Diseases. JRheum 2018, jrheum. 171389.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.